AstraZeneca's Calquence treads on Imbruvica's turf with second phase 3 CLL win
June 06, 2019 / Carly Helfand
AstraZeneca’s Calquence has been battling it out in mantle cell lymphoma since it won its first approval back in late 2017, but all along, the company has had its eye on another disease: chronic lymphocytic leukemia. And that’s where it’s scored its latest win. In a phase 3 trial, Calquence—combined with Roche’s Gazyva—beat out a regimen of chlorambucil chemotherapy and Gazyva at staving off disease progression in previously untreated CLL patients, AstraZeneca said Thursday. And the trial nailed a key secondary endpoint, too, showing solo Calquence could top the Gazyva-chemo combination at the same feat. The British drugmaker is keeping the details under wraps for now; they’ll debut at a future medical meeting. But in the meantime, later this month, the company plans to unveil full results from another Calquence CLL win that it top-lined in early May.